Alvelestat

Mereo BioPharma Group plc (NASDAQ:MREO) is a clinical-stage biopharmaceutical company focusing on rare diseases like osteogenesis imperfecta (OI) and alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Its lead asset, setrusumab, a monoclonal antibody for OI, has shown promising Phase 2 results, with pivotal studies ongoing. Alvelestat, a small molecule for AATD-associated lung disease, has also shown encouraging Phase 2 data, with a Phase 3 trial expected to start in late 2024. Mereo's financial position is stable, with cash reserves estimated to fund operations into 2027. The company is actively seeking partnerships to advance its pipeline and commercialize its products, with significant revenue potential from successful drug approvals.

Mereo BioPharma's CEO, Dr. Denise Scots-Knight, to participate in a Fireside Chat at the Jefferies London Healthcare Conference on Nov 19, 2024, at 10:30am ET / 03:30pm GMT. Live audio webcast available on the Company’s website, with an archived replay for two weeks.

Mereo BioPharma's Q3 2024 report shows no revenue, $9.4M operating loss, and $15M net loss. Focus on rare disease therapeutics with setrusumab and alvelestat in development. Expects significant operating losses and needs additional funding for R&D and potential commercialization.

Mereo BioPharma reports $80.5 million cash as of Sept 30, 2024, expected to fund operations into 2027. Setrusumab receives Breakthrough Therapy designation from the FDA for osteogenesis imperfecta treatment. Alvelestat expected to be Phase 3-ready by end of 2024.

Mereo BioPharma's CEO, Dr. Denise Scots-Knight, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on September 18. The company focuses on rare diseases, with product candidates setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo also has oncology candidates etigilimab and navicixizumab in development.

GVHD, a major complication post-allogeneic HSCT, involves acute (aGVHD) and chronic (cGVHD) forms, with distinct inflammatory and autoimmune/fibrotic features, respectively. Prevention strategies include CNI with MTX or MMF, ATG, PTCy, and graft manipulation. First-line treatment for aGVHD is corticosteroids, with Ruxolitinib for steroid-refractory cases. cGVHD treatment focuses on symptom control and preventing progression, with ECP and Ruxolitinib as options. Research highlights the importance of microbiota, biomarkers, and novel therapies targeting immune and non-immune pathways for improved outcomes.

Mereo BioPharma announced CEO Dr. Denise Scots-Knight will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company focuses on rare diseases, with key products setrusumab and alvelestat, and has partnerships for development and commercialization. Forward-looking statements caution about risks and uncertainties in clinical development and business operations.